Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.22.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Apr. 30, 2022
Segment Reporting [Abstract]  
SCHEDULE of SEGMENT INFORMATION

      2022       2021       2022       2021  
    For the Three Months Ended April 30,     For the Six Months
Ended April 30,
 
    2022     2021     2022     2021  
Net Loss:                                
CAR-T Therapeutics   $ (1,399 )   $ (1,446 )   $ (3,010 )   $ (2,406 )
Cancer Vaccines     (1,423 )     (662 )     (2,780 )     (1,569 )
Anti-Viral Therapeutics     (757 )     (310 )     (1,661 )     (791 )
Other     (9 )     (19 )     (16 )     97  
Total   $ (3,588 )   $ (2,437 )   $ (7,467 )   $ (4,669 )
Total operating costs and expenses   $ 3,589     $ 2,437     $ 7,469     $ 5,183  
Less non-cash share-based compensation     (1,681 )     (1,051 )     (4,036 )     (2,037 )
Operating costs and expenses excluding non-cash share-based compensation   $ 1,908     $ 1,386     $ 3,433     $ 3,146  
Operating costs and expenses excluding non-cash share based compensation:                                
CAR-T Therapeutics   $ 759     $ 935     $ 1,427     $ 1,492  
Cancer Vaccines     740       299       1,220       837  
Anti-Viral Therapeutics     402       138       774       409  
Other     7       14       12       408  
Total   $ 1,908     $ 1,386     $ 3,433     $ 3,146  

 

    April 30,
2022
    October 31,
2021
 
Total assets:                
CAR-T Therapeutics   $ 13,014     $ 15,068  
Cancer Vaccines     12,680       13,276  
Anti-Viral Therapeutics     6,883       7,368  
Other     220       545  
Total   $ 32,797     $ 36,257